VivePeptides logo

Research Collection

Growth Hormone Secretagogues

The pharmacological class of compounds studied for stimulating endogenous growth hormone release in preclinical models.

Growth Hormone Secretagogues are research compounds studied for their capacity to stimulate endogenous growth hormone release via two distinct receptor mechanism classes, GHRH receptor analogs and ghrelin receptor mimetics, featuring Sermorelin, the CJC 1295 No DAC plus Ipamorelin blend, and Tesamorelin, intended strictly for laboratory research use.

Reviewed by the VivePeptides Research DeskLast reviewed

Research Catalog

Compounds in this collection

Sermorelin research peptide vial

Sermorelin

$79.00View
CJC 1295 No DAC + Ipamorelin Blend research peptide vial

CJC 1295 No DAC + Ipamorelin Blend

$90.00View
Tesamorelin research peptide vial

Tesamorelin

$69.00View

Research Overview

GH Secretagogues as a Distinct Research Category

This research category encompasses peptide compounds that act on distinct receptor pathways to promote endogenous growth hormone pulsatility in experimental models, rather than compounds administered as exogenous hormone. Two mechanism classes dominate current investigation: growth hormone releasing hormone (GHRH) receptor analogs and ghrelin receptor (GHS-R1a) agonists, each triggering pituitary somatotroph activity through separate signaling cascades.

Interest in this category has grown as researchers examine pulsatile secretion, receptor desensitization, and combination dosing strategies in vitro and in animal models. This collection features Sermorelin, a GHRH receptor analog; the CJC 1295 No DAC plus Ipamorelin blend, pairing a GHRH analog with a selective ghrelin receptor agonist; and Tesamorelin, a stabilized GHRH analog studied for its resistance to enzymatic degradation.

VivePeptides sources each compound with third-party purity documentation to support reproducible research protocols across these mechanism classes.

Two Distinct Mechanism Classes

GHRH receptor analogs and ghrelin receptor agonists represent separate signaling pathways within this collection, allowing researchers to isolate or combine mechanisms of action in study design.

Blended Protocol Design

The CJC 1295 No DAC plus Ipamorelin blend pairs a GHRH analog with a ghrelin receptor agonist, a combination frequently referenced in dual-mechanism pulsatility research.

Purity and Reconstitution Standards

Each compound ships with third-party purity documentation, and researchers should account for reconstitution stability and cold-chain storage when designing time-course experiments.

Compound Comparison

How these compounds compare

CompoundMechanism ClassResearch FocusDistinguishing Feature
SermorelinGHRH receptor analogPulsatile GH release kineticsShort half-life, native GHRH sequence
CJC 1295 No DAC + Ipamorelin BlendGHRH analog plus ghrelin receptor agonistDual-pathway, additive GH pulse studiesCombines two complementary secretagogue mechanisms
TesamorelinStabilized GHRH receptor analogEnzymatic resistance and prolonged activityModified structure resists peptidase cleavage

Mechanism & Research Context

Receptor Mechanisms and Study Design Considerations

What distinguishes these mechanism classes is the receptor each compound engages: GHRH analogs bind the GHRH receptor on pituitary somatotrophs, while ghrelin mimetics act on the GHS-R1a receptor to amplify pulsatile release through a separate, synergistic pathway. Preclinical literature has examined how combining a GHRH analog with a ghrelin receptor agonist produces additive effects on growth hormone pulse amplitude compared to either mechanism alone, a rationale underlying blended-compound protocols.

Researchers selecting between compounds often weigh half-life differences: Tesamorelin's stabilized structure resists enzymatic cleavage, while Sermorelin's native-sequence fragment offers a shorter research window better suited to acute pulsatility studies. Study design considerations include reconstitution stability, storage temperature, and the choice of assay used to measure downstream IGF-1 response, all of which affect reproducibility when comparing GHRH-class and ghrelin-class results across experimental protocols.

Research FAQ

Frequently asked questions

What are growth hormone secretagogues?

Growth hormone secretagogues (GHS) are compounds that stimulate the pituitary gland to release endogenous growth hormone through GHRH receptor or ghrelin receptor pathways, rather than supplying growth hormone directly. Research has examined these mechanisms in cell culture and animal models to characterize pulsatile secretion patterns. This collection features three GHS peptides for laboratory research use.

What is the difference between GHRH analogs and ghrelin mimetics?

GHRH analogs, such as Sermorelin and Tesamorelin, bind the GHRH receptor on pituitary somatotrophs, while ghrelin mimetics like Ipamorelin act on the GHS-R1a receptor through a separate signaling cascade. Preclinical literature has examined combining both mechanism classes, as in the CJC 1295 No DAC plus Ipamorelin blend, to produce additive effects on GH pulse amplitude. The two classes are frequently studied together rather than as substitutes for one another.

Why is Tesamorelin considered a stabilized GHRH analog?

Tesamorelin's modified structure resists enzymatic degradation more effectively than native-sequence GHRH fragments, which researchers have linked to a longer window of receptor activity in study protocols. This structural stability has made it a reference compound in research examining prolonged GHRH receptor engagement. Its distinguishing feature relative to Sermorelin is this resistance to peptidase cleavage.

What does the CJC 1295 No DAC plus Ipamorelin blend investigate?

This blend combines a GHRH receptor analog with a selective ghrelin receptor agonist to investigate whether dual-pathway stimulation produces additive or synergistic effects on GH pulse amplitude compared to either mechanism alone. Researchers use it to model combination secretagogue protocols in vitro and in animal studies. The "No DAC" designation refers to the exclusion of the drug affinity complex modification present in some CJC 1295 variants.

How do researchers choose between GH secretagogue compounds?

Compound selection typically depends on the mechanism class under investigation, GHRH receptor engagement versus ghrelin receptor engagement, and the desired duration of receptor activity in the study design. Researchers examining acute pulsatility often reference Sermorelin's shorter research window, while those studying prolonged engagement reference Tesamorelin's enzymatic resistance. Combination studies frequently reference the CJC 1295 No DAC plus Ipamorelin blend to compare dual-mechanism outcomes.

How should GH secretagogue peptides be stored for research use?

Lyophilized GH secretagogue peptides should be stored frozen and protected from light prior to reconstitution, with reconstituted solutions kept refrigerated and used within the timeframe established by the individual research protocol. Reconstitution stability varies by compound structure, which is a relevant variable when designing time-course experiments. Researchers should document storage conditions alongside assay results to support reproducibility.

Related Research Collections

Continue exploring

Copper PeptidesMitochondrial PeptidesAntimicrobial PeptidesAntioxidant Peptides

All products are sold strictly for laboratory and scientific research use only. Not for human or animal consumption, diagnostic, or therapeutic use. Nothing on this page constitutes medical advice or a health claim.